Results 241 to 250 of about 754,612 (422)

Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics

Clinical Pharmacology &Therapeutics, EarlyView.
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou, Rohit Rao, Monica E. Shapiro, Nessy Tania, Cody Herron, Cynthia J. Musante, Jim H. Hughes   +6 more
wiley   +1 more source

Functions of alveolar macrophages in patients with interstitial lung diseases.

, 1990
Shigee Hosoya, Yasunari Nakata, Mikio Kataoka, Tohru Hioka, T. Maeda, Hiroshi Nishizaki, K Shiomi, Shinya Tada, T Ohnoshi, I Kimura   +9 more
openalex   +2 more sources

Thoracic ultrasound in interstitial lung disease. [PDF]

Breathe (Sheff)
Shah DJ, Esposito A, Pitaktong A, Sauthoff H.   +3 more
europepmc   +1 more source

A Genetic Twist: Cytologic Evaluation of Pancreatic Adenocarcinoma and Steatohepatitic Hepatocellular Carcinoma in a Patient With a Rare POLE Mutation

Diagnostic Cytopathology, EarlyView.
ABSTRACT Mutations in the DNA polymerase epsilon (POLE) gene are associated with an increased risk of various malignancies, including colorectal and other gastrointestinal, endometrial, ovarian, breast, and brain cancers. In extremely rare cases, POLE mutations have also been associated with pancreatic and hepatobiliary carcinomas.
Lynn Messersmith, Areeba H. Rizvi, Dina El‐Rayes, Jimmie Stewart III   +3 more
wiley   +1 more source

Remote Patient Monitoring for Managing Interstitial Lung DiseaseTake-Home Points

CHEST Pulmonary
Background: Hybrid health care delivery uses a combination of in-person and telehealth visits to deliver interstitial lung disease (ILD) care efficiently and flexibly.
Genevieve Gillett, MD, Rupal J. Shah, MD, Alison M. DeDent, MD, Erica Farrand, MD   +3 more
doaj  

Interstitial lung diseases : Advances in diagnosis and treatment.Eosinophilic pneumonia.

, 1994
津田 富康, 宮崎 英士
openalex   +2 more sources

Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers or healthy volunteers [PDF]

, 2000
Sandra Brunelleschi, Roberta Nicali, Luisa Lavagno, I Viano, Elisa Pozzi, L Gagliardi, P Ghio, Carlo Albera   +7 more
openalex   +1 more source

The lung microbiome in interstitial lung disease. [PDF]

Breathe (Sheff)
Mikhail SG, O'Dwyer DN.
europepmc   +1 more source

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

Developmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito, Yukio Fujiwara, Yasuka L. Yamaguchi, Satomi S. Tanaka, Kyoko Miura, Yoshiyuki Hizukuri, Kyoko Yamashiro, Yasuhiro Hayashi, Yuta Nakashima, Yoshihiro Komohara   +9 more
wiley   +1 more source

Immune mechanisms in interstitial lung diseases [PDF]

, 2000
Gianpietro Semenzato, Fausto Adami, Nilla Maschio, Carlo Agostini   +3 more
openalex   +1 more source